AGF Investments Inc. trimmed its position in shares of Zoetis (NYSE:ZTS) by 15.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 120,376 shares of the company’s stock after selling 21,576 shares during the quarter. AGF Investments Inc.’s holdings in Zoetis were worth $10,053,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Zoetis during the fourth quarter valued at approximately $108,000. We Are One Seven LLC acquired a new stake in Zoetis in the fourth quarter worth $120,000. Premia Global Advisors LLC acquired a new stake in Zoetis in the fourth quarter worth $122,000. Icon Wealth Partners LLC acquired a new stake in Zoetis in the fourth quarter worth $127,000. Finally, Mckinley Capital Management LLC Delaware acquired a new stake in shares of Zoetis during the first quarter worth $134,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts recently weighed in on the stock. Citigroup reaffirmed a “buy” rating and issued a $98.00 target price (up previously from $85.00) on shares of Zoetis in a research report on Thursday, April 19th. Hilliard Lyons downgraded shares of Zoetis to a “neutral” rating in a report on Thursday, April 19th. They noted that the move was a valuation call. Cantor Fitzgerald set a $90.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Tuesday, April 24th. Morgan Stanley cut shares of Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 target price for the company. in a research report on Monday, March 19th. They noted that the move was a valuation call. Finally, Craig Hallum reiterated a “buy” rating and set a $94.00 price objective (up from $87.00) on shares of Zoetis in a research report on Wednesday, April 25th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $82.67.
Shares of ZTS stock opened at $82.95 on Friday. The company has a current ratio of 4.27, a quick ratio of 2.83 and a debt-to-equity ratio of 2.51. The firm has a market cap of $40.17 billion, a PE ratio of 34.56, a price-to-earnings-growth ratio of 1.83 and a beta of 0.97. Zoetis has a 12 month low of $82.05 and a 12 month high of $83.07.
Zoetis (NYSE:ZTS) last issued its earnings results on Wednesday, May 2nd. The company reported $0.75 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.69 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.35 billion. Zoetis had a return on equity of 68.51% and a net margin of 17.97%. Zoetis’s revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.53 EPS. analysts expect that Zoetis will post 3.06 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, July 20th will be paid a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, July 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.61%. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.
In related news, insider Roman Trawicki sold 23,885 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $82.00, for a total transaction of $1,958,570.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 35,663 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total value of $2,889,416.26. Following the transaction, the executive vice president now owns 49,919 shares of the company’s stock, valued at $4,044,437.38. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 117,829 shares of company stock valued at $9,626,877. 0.35% of the stock is currently owned by corporate insiders.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.